Hepatic Manifestations and Effect of Long COVID-19 on Patients With Chronic Liver Disease

Assiut University

Status: Active, not recruiting

Conditions: COVID-19

Treatments: Diagnostic Test: liver function , prothrombin time , INR , US .

Study type: Observational

Funder types: Other

Identifiers

NCT04998214

liver in COVID-19

Details and patient eligibility

About

To measure the frequency of persistent liver dysfunction (raised liver enzymes, serum albumin, prothrombin time, etc) in recovered COVID -19 patients.

To compare the hepatic manifestations in post COVID -19 patients with and without liver disease

Full description

The digestive tract, particularly the liver, has recently been reported to be affected by SARS-CoV-2. Although abnormal liver enzymes were regularly described as an extra-pulmonary clinical feature, and almost one half of patients experienced grades of hepatic injury. liver damage in patients with SARS infections was primarily manifested in the mild and moderate elevation of alanine and/or aspartate aminotransferases (ALT and AST) with some degree of hypoalbuminemia and hyperbilirubinemia during the early stage of the illness.

Enrollment: 65 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients previously diagnosed by COVID 19 eg : PCR and / or HRCT chest, lab of more than 1 month duration.

Exclusion criteria

• Patients less than 18 y.
• Patients with acute COVID 19.

Trial design

65 participants in 2 patient groups

control group non cirrhotic

Description:

compare liver function 1m after COVID-19 and that at beginning of infection

Treatment:

Diagnostic Test: liver function , prothrombin time , INR , US .

cirrhotic patients

Description:

compare liver function 1m after COVID-19 and that at beginning of infection

Treatment:

Diagnostic Test: liver function , prothrombin time , INR , US .